Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of KRRO-121 in Healthy Volunteers and Patients With Urea Cycle Disorders

NCT07773246 is registered in ClinicalTrials.gov with Korro Bio, Inc. as lead sponsor.

NCT NCT07773246
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07773246 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of KRRO-121 in Healthy Volunteers and Patients With Urea Cycle Disorders
Lead sponsor
Korro Bio, Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
September 28, 2026
Completion date
September 30, 2027
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

arginase 1 deficiency, argininosuccinate lyase deficiency, argininosuccinate synthase, carbamylphosphate synthetase i, citrin deficiency, n-acetyl glutamate - synthetase, nags deficiency, ornithine transcarbamylase (otc) deficiency, ornithine transporter mitochondrial 1, urea cycle disorders, urea cycle disorders, inborn